Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesDermatologymhn Alopecia Areata Prior Auth Update | OpenPayer
    Ask Trek AI about this page
    CurrentmhnPolicy HNCA.CP.CPA.04

    Clinical Policy: Alopecia Areata Treatments

    Customize your policy alerts

    Sign up for mhn Policy HNCA.CP.CPA.04 alerts

    Get alerted when Policy HNCA.CP.CPA.04 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and prior authorization requirements for baricitinib (Olumiant), ritlecitinib (Litfulo), and deuruxolitinib (Leqselvi) for treating alopecia areata for applicable commercial and HIM lines of business.

    Policy Summary
    Payermhn
    PolicyClinical Policy: Alopecia Areata Treatments
    Policy CodePolicy HNCA.CP.CPA.04
    Change TypeBenefit exclusion added for HIM
    Effective DateSep 25, 2025
    Last ReviewAug 25, 2025
    Next Review DateAug 25, 2025
    Key ActionSubmit prior authorization with documentation showing severe alopecia areata (≥50% scalp hair loss), prior therapy trial, dermatology prescribing/consultation, and adherence to dose limits.
    SourceLink
    POLICY UPDATE CHANGES

    Health Insurance Marketplace (HIM) use of these products for alopecia areata is a benefit exclusion and will not be authorized because it is considered cosmetic in nature.

    3JAK inhibitors requiring prior authorization
    >50%Severe AA threshold
    12 moContinued therapy approval
    ≥12/18

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Age restrictions
    Agent-specificDose limits

    Coverage Criteria

    Initial Therapy — Covered when ALL of the following are met.

    Covered when ALL of the following are met:

    Initial therapy for severe alopecia areata: Member has a diagnosis of severe alopecia areata (defined as >50% scalp hair loss); current episode lasting >6 months; prescribed by or in consultation with a dermatologist; age meets product-specific minimums (Litfulo ≥12 years; Olumiant and Leqselvi ≥18 years); member has tried at least ONE of the following: (a) a conventional systemic therapy (examples include corticosteroids, methotrexate, cyclosporine) — exception: this trial may be waived if the patient has already tried Olumiant, Litfulo, or Leqselvi; OR (b) a high- or super-high potency topical corticosteroid; OR (c) topical immunotherapy (e.g., DPCP or SADBE); member will not use the requested product in combination with other JAK inhibitors (including topical JAK inhibitors), biologic immunomodulators (DMARDs), or potent immunosuppressants (e.g., azathioprine, cyclosporine); dose does not exceed product-specific maximums (Olumiant ≤4 mg/day; Litfulo ≤50 mg/day; Leqselvi ≤16 mg/day).See dose limits and severity threshold

    Provider must submit supporting documentation (office chart notes, lab results, or other clinical information).

    Continuation Therapy — Continued therapy covered when ALL of the following are met.

    Continued therapy is covered when ALL of the following are met:

    Continued therapy: Member is currently receiving the medication via Centene benefit, or documentation shows current use of Olumiant, Litfulo, or Leqselvi for a covered indication for at least 30 days; member is responding positively to therapy as evidenced by improvement in extent and density of hair regrowth compared to baseline; member will not be using the requested product in combination with other JAK inhibitors (including topical JAK inhibitors), biologic immunomodulators (DMARDs), or potent immunosuppressants (e.g., azathioprine, cyclosporine); if the request is for a dose increase, the new dose does not exceed product-specific maximums (Olumiant ≤4 mg/day; Litfulo ≤50 mg/day; Leqselvi ≤16 mg/day).30 days on therapy; 12 month approval

    Approval duration: 12 months.

    Requests for treatment of alopecia areata with the JAK inhibitors listed in this policy will be evaluated under the policy criteria; however, Health Insurance Marketplace (HIM) members are excluded from coverage for these indications because use for alopecia areata is considered cosmetic and will not be authorized. Provider documentation supporting medical necessity must still be submitted for non‑HIM members (see Provider Actions).

    Combination therapy with other systemic immunosuppressive agents is not permitted. Specifically, concomitant use with biological DMARDs, other JAK inhibitors, or other potent immunosuppressants is prohibited due to additive immunosuppression and associated increased risks. Requests that propose combination use will be denied.

    Prior authorization is required for baricitinib (Olumiant), ritlecitinib (Litfulo), and deuruxolitinib (Leqselvi) and approvals are contingent upon meeting the policy's clinical criteria (severity threshold, prior therapy requirements, prescriber specialty/consultation, age restrictions, and product‑specific dose limits).

    This policy does not authorize use of the listed JAK inhibitors for non‑FDA approved indications unless such use is specifically addressed by the applicable off‑label or formulary policies. For commercial lines of business, refer to off‑label policy CP.CPA.09; requests lacking sufficient documentation of efficacy and safety per those policies will not be approved.

    Exercise caution and do not approve requests that combine a JAK inhibitor with other potent immunosuppressive therapies. Combination use with biologic DMARDs, other JAK inhibitors, or potent immunosuppressants is not authorized because of additive immunosuppression, an increased risk of malignancy, and an increased risk of serious infections. Such combination therapy will be denied.

    Coding and Severity Thresholds

    Severe AA threshold — percent scalp hair loss used to define severity
    Threshold≥ 50% scalp hair loss defines severe alopecia areata
    Mild AA≤ 20% scalp hair loss
    Moderate AA21%–49% scalp hair loss
    Severe AA range50%–100% scalp hair loss
    Severe AA defined as >50% scalp hair loss (50-100%).
    Primary definition>50% scalp hair loss (50%–100%) defines severe alopecia areata
    Severity scale sourceAppendix A: Alopecia Areata (AA) Severity Scale

    Provider Actions and Requirements

    Prior Authorization

    Prior authorization required for Olumiant, Litfulo, and Leqselvi

    Prior authorization is required for Baricitinib (Olumiant), Ritlecitinib (Litfulo), and Deuruxolitinib (Leqselvi) for the treatment of alopecia areata. Approval is contingent on meeting the policy criteria including diagnosis of severe AA (>50% scalp hair loss), episode >6 months, dermatology prescribing/consultation, product-specific age limits, trial of at least one listed prior therapy, prohibition on combination immunosuppressive therapy, and adherence to product-specific dose limits.

    • Affected products: Baricitinib (Olumiant), Ritlecitinib (Litfulo), Deuruxolitinib (Leqselvi).
    • Approval requires meeting all policy criteria (severity, duration, prescriber specialty, age, prior therapy, combination use restrictions, and dose limits).
    Step Therapy

    Prior therapy required (one of listed options)

    Member must have tried at least one of the following prior therapies before approval: a conventional systemic therapy, a high- or super-high potency topical corticosteroid, or topical immunotherapy (e.g., DPCP or SADBE).

    Background

    Alopecia areata severity is classified by the percent of scalp hair loss; severe alopecia areata is defined as ≥ 50% scalp hair loss (extent of scalp hair loss between approximately 50% and 100%).

    Janus kinase (JAK) inhibitors including baricitinib (Olumiant), ritlecitinib (Litfulo), and deuruxolitinib (Leqselvi) are FDA‑approved for severe alopecia areata in specified age groups and have product‑specific dosing and age restrictions. Use is subject to prior authorization and the policy’s criteria, including requirements for prior therapy, dermatology involvement, and prohibition of combination immunosuppressive regimens.

    Definitions

    Definition of severe alopecia areata
    Definition (concise)>50% scalp hair loss (50%–100%) = Severe alopecia areata
    Related categoriesMild: ≤20%; Moderate: 21%–49%
    Severity upgrade criteriaIncrease severity rating by one level if negative psychosocial impact, eyebrow/eyelash involvement, inadequate response after ≥6 months, or diffuse positive hair pull test
    Policy Summary
    Payermhn
    PolicyClinical Policy: Alopecia Areata Treatments
    Policy CodePolicy HNCA.CP.CPA.04
    Change TypeBenefit exclusion added for HIM
    Effective DateSep 25, 2025
    Last ReviewAug 25, 2025
    Next Review DateAug 25, 2025
    Key ActionSubmit prior authorization with documentation showing severe alopecia areata (≥50% scalp hair loss), prior therapy trial, dermatology prescribing/consultation, and adherence to dose limits.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Severity ThresholdsProvider Actions and RequirementsBackgroundDefinitions
    ImplicationPatients with ≥50% scalp hair loss meet the policy's severe AA criterion for therapy consideration
    • Conventional systemic therapy (examples: corticosteroids, methotrexate, cyclosporine).
    • High- or super-high potency topical corticosteroid.
    • Topical immunotherapy (e.g., diphenylcyclopropenone (DPCP) or squaric acid dibutyl ester (SADBE)).
    • Exception: requirement for a trial of a conventional systemic agent may be waived if the patient has already tried Olumiant, Litfulo, or Leqselvi.
    Documentation Required

    Submit clinical documentation to support approval

    Provider must submit supporting documentation such as office chart notes, laboratory results, or other clinical information demonstrating that the member meets all approval criteria.

    • Documentation should verify diagnosis of severe AA (>50% scalp hair loss), duration of current episode (>6 months), dermatology involvement, prior therapy trials, and current dosing.
    • Include labs or other clinical data as needed to support safety and appropriateness.
    Denial Risk

    Exclusions that will trigger denial

    Certain requests will be denied: use of these products for Health Insurance Marketplace (HIM) members for alopecia areata is excluded as cosmetic; combination use with biologic DMARDs, other JAK inhibitors (including topical JAK inhibitors), or potent immunosuppressants is not authorized.

    • HIM benefit exclusion: use of Olumiant, Litfulo, or Leqselvi for AA in Health Insurance Marketplace members will not be authorized as it is considered cosmetic.
    • Combination therapy with biologic DMARDs, other JAK inhibitors, or potent immunosuppressants (e.g., azathioprine, cyclosporine) is prohibited and requests for such use will be denied.